Drug: Lenalidomide - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Compound: Lenalidomide

Drug Target: CRBN

Drug Target pathway: Protein stability and degradation

GDSC2
GDSC1

Tissue specific analysis

Each circle represents an association between a genomic marker and drug sensitivity analysed using ANOVA. Different ANOVA analyses use selected context specific genomic markers as features. Use the dropdown to select a tissue specific analysis or a pan-cancer analysis.

Retrieving drug sensitivity data...

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer

Compound: Lenalidomide

Drug Target: CRBN

Drug Target pathway: Protein stability and degradation

Dataset

Tissue specific analysis